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Won Young Kim1 & Korean shock society (Koss) Investigators*
the objective of this study was to evaluate the prognostic value of C-reactive protein (CRp), 
procalcitonin (pCt), and their combination for mortality in patients with septic shock. this multicenter, 
prospective, observational study was conducted between November 2015 and December 2017. A total 
of 1,772 septic shock patients were included, and the overall 28-day mortality was 20.7%. Although 
both CRP and PCT were elevated in the non-survivor group, only CRP had statistical significance 
(11.9 mg/dL vs. 14.7 mg/dL, p = 0.003, 6.4 ng/mL vs. 8.2 ng/mL, p = 0.508). Multivariate analysis 
showed that CRp and pCt were not independent prognostic markers. In the subgroup analysis of the 
CRP and PCT combination matrix using their optimal cut-off values (CRP 14.0 mg/dL, PCT 17.0 ng/dL), 
both CRP and PCT elevated showed significantly higher mortality (Odds ratio 1.552 [95% Confidence 
intervals 1.184–2.035]) than both CRP and PCT not elevated (p = 0.001) and only PCT elevated 
(p = 0.007). However, both CRP and PCT elevated was also not an independent predictor in multivariate 
analysis. Initial levels of CRp and pCt alone and their combinations in septic shock patients had a 
limitation to predict 28-day mortality. Future research is needed to determine new biomarkers for early 
prognostication in patients with septic shock.
Sepsis is a life threatening organ dysfunction evoked by abnormal host response to infection, and the Sequential 
Organ Failure Assessment (SOFA) score is used to calculate the degree of organ dysfunction in sepsis1,2. Septic 
shock is defined as a subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are 
profound enough to substantially increase mortality2. We can evaluate the degree of shock by measuring mean 
arterial blood pressure as a circulatory abnormality and serum lactate level as a cellular metabolic abnormality3. 
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However, proven biomarkers that reflect the severity of infection in patients with sepsis have not yet been identi-
fied, and current guidelines by the Surviving Sepsis Campaign do not provide any biomarkers that can evaluate or 
identify an infection, except procalcitonin (PCT) for indicating the timing of de-escalating antibiotics3.
C-reactive protein (CRP) is a traditional biomarker which is elevated in inflammatory states including rheu-
matoid arthritis and infection4. Aside from its roles as a biomarker, CRP also functions as a part of the defense 
mechanism against inflammation and pathogen invasion5. However, CRP has low specificity for diagnosing sep-
sis, and the plasma level of CRP is not a reliable indicator for the degree of systemic inflammation6.
PCT is used as an indicator for antibiotics treatment because the level of PCT is higher in fungal, parasitic, and 
bacterial infections than in viral infections. Accordingly, high early levels of PCT in sepsis have been suggested 
to be associated with unfavorable prognosis7. Nevertheless, early PCT levels are subject to alteration by the type 
and severity of the initial cause of the sepsis and not necessarily the severity of the sepsis itself; therefore, it is not 
recommended to utilize early PCT level as a definite indicator of prognosis8.
Research about the diagnostic ability of CRP and PCT has been conducted in sepsis, but data on the early 
prognostic value of CRP and PCT are lacking. This study evaluated the prognostic values of CRP and PCT for 
mortality prediction in septic shock cases.
Results
Of the 2,264 eligible patients in the Korean Shock Society (KoSS) septic shock registry, we excluded 124 patients 
due to missing 28-day mortality data and 367 patients due to missing CRP or PCT data. Finally, 1,772 patients 
were included and divided into 1,406 (79.3%) survivors and 366 (20.7%) non-survivors. (Fig. 1)
The non-survivor group was male predominant (63.7% vs. 57.8% p = 0.041). Subjects were older (70.1 ± 13.0 
years vs. 66.8 ± 13.7 years, p < 0.001) and had more co-morbidities, including diabetes and chronic pulmonary 
disease (35.5% vs. 28.5%, p = 0.009; 12.3% vs. 7.0%, p = 0.001; respectively), than the survivors. Their initial heart 
rate was faster (112.2 ± 25.0 vs. 104.2 ± 23.0, p < 0.001). Pneumonia was more frequent in the non-survivors 
(48.1% vs. 27.3%, p < 0.001); however, urinary tract infection and hepatobiliary and pancreas infection were 
more common in the survivors (19.1% vs. 26.7%, p = 0.001; 16.4% vs. 21.1%, p = 0.048; respectively). The severity 
scores, including maximum SOFA and Acute Physiology and Chronic Health evaluation (APACHE) II scores 
were higher in the non-survivor group (10.0 [8.0–13.0] vs. 7.0 [5.0–10.0], p < 0.001; 24.0 [18.0–34.0] vs. 18.0 
[13.0–24.0], p < 0.001; respectively) (Table 1).
Serum creatinine, blood urea nitrogen, aspartate transaminase, and initial lactate levels were significantly 
higher in the non-survivors (1.3 [0.9–2.0] vs. 1.6 [1.0–2.6], p < 0.001; 25.5 [17.0–37.0] vs. 33.0 [21.7–49.0], 
p < 0.001; 38.0 [24.0–76.0] vs. 44.5 [27.0–105.0], p = 0.001; 3.0 [1.8–4.9] vs. 4.9 [2.7–8.3], p < 0.001; respectively). 
However white blood cell count was not different (10.2 [5.3–16.5] vs. 9.8 [4.2–17.0], p = 0.342; Table 1). The 
initial PCT level also did not differ significantly (odds ratios (OR) 0.999 [95% confidence intervals (CI) 0.997–
1.001]); however, initial CRP level was significantly higher in the non-survivors (OR 1.013 [95% CI 1.004–1.022]). 
Although in univariate logistic regression, CRP increased the 28-day mortality rate it was not an independent 
predictor of 28-day mortality in multivariate logistic regression analysis (Table 2). The optimal cut-off values of 
CRP and PCT in receiver operating characteristic (ROC) curve were 14 mg/dL and 17 ng/dL, respectively. The 
sensitivity, specificity, positive predictive value, and negative predictive value of CRP were 52.5%, 56.4%, 23.9%, 
and 82.0%, respectively, and those of PCT were 39.1%, 65.7%, 22.8%, and 80.5, respectively.
The combination matrix of CRP and PCT was compared to determine the 28-day mortality of each group 
(Fig. 2). The OR of both CRP and PCT elevated was 1.552 (95% CI 1.184–2.035), and the mortality rate was 
26.9%. The 28-day mortality of both CRP and PCT elevated was significantly higher than that of only PCT ele-
vated (17.8%) and both CRP and PCT not elevated (18.1%). However, the 28-day mortality of patients with 
only CRP elevated was 21.5% which was not significantly different from those with both CRP and PCT elevated 
(p = 0.079) (Fig. 2, Table 3). Nevertheless, in the multivariate logistic regression analysis, both CRP and PCT 
elevated was not an independent predictor of 28-day mortality.
Figure 1. Diagram of included patients. Abbreviations: CRP, C-reactive protein; PCT, Procalcitonin.
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Discussion
In our study, the initial levels of CRP and PCT did not show significant association with 28-day mortality. When we 
compared the combination matrix of CRP and PCT using the optimal cut-off values, the mortality rate of patients 
with elevated CRP and PCT was significantly higher than that of patients with non-elevated CRP and PCT or only 
elevated PCT. However, both CRP and PCT elevated was not an independent predictor of 28-day mortality.
Sepsis is an infectious condition associated with organ dysfunction; therefore, a diagnosis of infection is 
crucial. Most sepsis-related infection symptoms and variables such as fever and tachycardia are not necessarily 
sepsis-specific. Therefore, in order to increase the accuracy of sepsis diagnosis, physicians should survey for other 
indicators such as biomarkers (e.g., CRP, PCT), imaging data (e.g., X-ray), and organ dysfunction9. A previous 
study showed that patients with mixed bacterial pneumonia had significantly higher serum levels of CRP and 
PCT than in those with viral infection alone10. Another study in neonatal sepsis patients also reported that both 
CRP and PCT showed relatively good performance in discriminating proven sepsis from controls, and their com-
bination increased the accuracy of neonatal sepsis diagnoses11. However, the primary outcome of both previous 
studies was diagnosis of infection and sepsis. The early prognostic value of CRP and PCT in septic shock cases 
that received protocol-driven resuscitation bundle therapy at emergency departments (EDs) remains unclear. 
Our current data show that CRP, PCT, and their combination have limited ability in predicting mortality in septic 
shock cases. CRP was associated with 28-day mortality in univariate models only and not in the multivariate 
model. We speculate that initial CRP and PCT might be measured too early to reflect disease severity. However, 
that initial levels of CRP and PCT were obtained before resuscitation, specifically before antibiotics administra-
tion which can influence CRP and PCT levels, could be considered strength of this study. PCT induction occurs 
at approximately 2–4 hours after the onset of sepsis, and peaks at 24–48 hours6. Thus, because CRP elevation is 
also expected to occur 24–48 hours after the initial inflammatory response4, initial CRP and PCT may not be 
considered to be useful markers in patients with acute and critical conditions.
Characteristics Total (n = 1,772) Survivors (n = 1,406) Non-survivors (n = 366) p-value
Age, years 67.5 ± 13.6 66.8 ± 13.7 70.1 ± 13.0 <0.001
Male 1,045 (59.0) 812 (57.8) 233 (63.7) 0.041
Past medical history
Hypertension 723 (40.8) 560 (39.8) 163 (44.5) 0.103
Diabetes 531 (30.0) 401 (28.5) 130 (35.5) 0.009
Coronary artery disease 226 (12.8) 177 (12.6) 49 (13.4) 0.683
Stroke 211 (11.9) 160 (11.4) 51 (13.9) 0.179
Chronic pulmonary disease 144 (8.1) 99 (7.0) 45 (12.3) 0.001
Metastatic cancer 434 (24.5) 331 (23.5) 103 (28.1) 0.068
Vital signs at shock recognition
Systolic blood pressure, mmHg 89.4 ± 23.1 89.1 ± 22.3 90.4 ± 26.1 0.384
Diastolic blood pressure, mmHg 54.3 ± 16.0 53.7 ± 14.9 56.4 ± 19.6 0.016
Pulse rate, beats/min 105.8 ± 23.6 104.2 ± 23.0 112.2 ± 25.0 <0.001
Infection focus
Pneumonia 560 (31.6) 384 (27.3) 176 (48.1) <0.001
Urinary tract infection 446 (25.2) 376 (26.7) 70 (19.1) 0.001
Hepatobiliary and pancreas infection 356 (20.1) 296 (21.1) 60 (16.4) 0.048
Gastrointestinal infection 303 (17.1) 230 (16.4) 73 (19.9) 0.104
Laboratory findings
White blood cell count (×103/μL) 10.2 [5.1–16.6] 10.2 [5.3–16.5] 9.8 [4.2–17.0] 0.342
Hemoglobin, g/dL 11.0 ± 2.5 11.1 ± 2.4 10.7 ± 2.8 0.003
Creatinine, mg/dL 1.3 [0.9–2.2] 1.3 [0.9–2.0] 1.6 [1.0–2.6] <0.001
Blood urea nitrogen, mg/dL 26.6 [18.0–40.4] 25.5 [17.0–37.0] 33.0 [21.7–49.0] <0.001
Aspartate transaminase, IU/L 39.0 [24.0–82.0] 38.0 [24.0–76.0] 44.5 [27.0–105.0] 0.001
Alanine transaminase, IU/L 25.0 [14.0–54.0] 26.0 [15.0–52.0] 25.0 [14.0–58.3] 0.825
Initial lactate level, mmol/L 3.3 [1.9–5.4] 3.0 [1.8–4.9] 4.9 [2.7–8.3] <0.001
C-reactive protein, mg/dL 12.3 [4.6–21.8] 11.9 [4.3–21.0] 14.7 [5.8–25.1] 0.003
Procalcitonin, ng/mL 6.8 [1.1–27.6] 6.4 [1.0–26.8] 8.2 [1.1–30.7] 0.508
Severity score
Maximum SOFA 8.0 [5.0–11.0] 7.0 [5.0–10.0] 10.0 [8.0–13.0] <0.001
APACHE-II score 19.0 [14.0–26.0] 18.0 [13.0–24.0] 24.0 [18.0–34.0] <0.001
Table 1. Baseline and clinical characteristics of the study population grouped into survivors and non-
survivors. Values were expressed as means ± standard deviation, medians [interquartile range], or numbers (%) 
Abbreviations: SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health 
Evaluation.
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A systemic review and meta-analysis study showed that PCT levels were significantly different between sur-
viving and non-surviving sepsis patients12. Among 25 analyzed studies, only four were conducted at EDs. Because 
most studies were conducted at intensive care units (ICUs), the measured time of PCT is doubtful. Additionally, 
the heterogeneity among the studies was very high. The mortality reported in the studies ranged from 13% to 
69%, and the severity of infection ranged from sepsis to septic shock. Another recent study also reported that the 
levels of PCT and CRP at admission showed association with mortality. However, their obtained sample time was 
the morning after admission, and mortality was excessively high, sepsis was 43.33%, and septic shock was 75%13. 
In contrast, a recent study performed in pediatrics reported that median CRP and PCT were not associated with 
mortality; overall mortality was 33.3%, and samples were obtained on the first day of ICU admission14.
Because of these varying results, other studies using biomarkers have been conducted to predict prognosis. 
Huang et al. studied PCT clearance. In their study, although PCT levels on days 1, 3, and 5 were not associated with 
prognosis, PCT clearance rates at days 3 and 5 were significantly higher in the survivor group15. Another study also 
evaluated the PCT trend and reported that a decrease in the initial PCT level of more than 80% on day 4, rather 
than initial PCT level, was predictive for survival16. Hahn et al. demonstrated a PCT to CRP ratio to detect late 
onset neonatal sepsis. In their study, the area under the curve of PCT/CRP was 0.73 for distinguishing between 
proven and suspected sepsis11. However, this study did not report the prognostic value of the PCT/CRP ratio.
In our study, we evaluated the combination of CRP and PCT for their prognostic power in predicting mortal-
ity. We found that patients who had elevation of both CRP and PCT had significantly higher mortality rate than 
did the other groups, except those who had elevation of CRP only. Because CRP is associated with immunity4 
Characteristics Univariate OR [95% CI] Multivariate OR [95% CI] p-value
Age, years 1.019 [1.010–1.028] 1.014 [1.003–1.025] 0.009
Chronic lung disease 1.851 [1.275–2.687]
Pulse rate, beats/min 1.014 1.009–1.019]
Pneumonia 2.465 [1.947–3.122] 2.113 [1.609–2.775] <0.001
Urinary tract infection 0.648 [0.487–0.862]
Maximum SOFA 1.242 [1.201–1.284] 1.163 [1.109–1.220] <0.001
APACHE-II 1.089 [1.074–1.103] 1.025 [1.006–1.044] 0.008
Creatinine, mg/dL 1.150 [1.072–1.234] 0.876 [0.777–0.988] 0.031
Blood urea nitrogen, mg/dL 1.016 [1.011–1.021]
Aspartate transaminase, IU/L 1.000 [1.000–1.001]
Initial lactate level, mmol/L 1.211 [1.169–1.254] 1.163 [1.119–1.208] <0.001
C-reactive protein, mg/dL 1.013 [1.004–1.022]
Procalcitonin, ng/mL 0.999 [0.997–1.001]
Table 2. Univariate and multivariate analysis for 28-day mortality. Logistic regression analysis with backward 
elimination method. Abbreviations: OR, odds ratio; CI, confidence interval; SOFA, Sequential Organ Failure 
Assessment; APACHE, Acute Physiology and Chronic Health Evaluation.
Figure 2. Mortality of procalcitonin (PCT), C-reactive protein (CRP), and their combinations. Optimal cut 
off of CRP elevation was defined as ≥14 mg/dL and PCT elevation was defined as ≥17 ng/mL. Overall 28-day 
mortality was 20.7%. The mortality rates of both CRP and PCT not elevated, only CRP elevated, only PCT 
elevated, and both CRP and PCT elevated were 18.1%, 21.5%, 17.8%, and 26.9%, respectively. The mortality of 
both CRP and PCT elevated was significantly higher than for both not elevated and only PCT elevated.
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and reflects an inflammatory condition5 which is associated with the host defense mechanism, it might more 
directly influence mortality, whereas PCT is a very sensitive biomarker of bacterial infection6, Moreover, antibi-
otics administration time could confound the spread of bacterial infection therefore, it might confound the initial 
PCT value. If so, the PCT variation trend, rather than initial value, may be more associated with prognosis as 
shown previously16. In this study, because of the nature of a prospective multi-center observational study, we were 
unable to determine a trend for PCT. In contrast, previous studies reported that several days were needed for the 
CRP levels to peak, whereas PCT levels peaked at 24–48 hours after sepsis, despite induction after approximately 
2–4 hours6. Therefore, initial CRP and PCT levels in this study might be underestimated.
As is well known, PCT and CRP are suitable markers for the diagnosis of sepsis, and they have been used 
for the early detection of infection and guiding of antibiotics therapy. However, in this study we were unable to 
confirm a limited ability to predict mortality in septic shock patients, specifically considering initial CRP and 
PCT levels. Although infection is a cause of sepsis, the degree of shock or organ failure as a result of septic shock 
may be more suitable for predicting mortality. Future research will most likely focus on the development of new 
biomarkers or combinations of markers with clinical signs for predicting prognosis of early septic shock and 
guiding therapy.
This study had some limitations. Due to its prospective observational design, we were unable to obtain addi-
tional laboratory data such as repeated CRP and PCT levels. Analyzing the biomarkers several days after sep-
sis development may show an association with mortality. However, in the clinical setting, because factors are 
required which can predict mortality early-on, biomarkers obtained several days after diagnosis are not helpful. 
Moreover, during septic shock management various factors influence mortality; therefore, more valuable results 
may be obtained if possible risk factors can be controlled.
Characteristics
Both CRP and PCT 
not elevated (n = 691)
Only CRP 
elevateda (n = 455)
Only PCT 
elevatedb (n = 276)
Both CRP and PCT 
elevated (n = 350) p-value
Age, years 66.9 ± 13.9 68.9 ± 13.0 67.8 ± 13.9 66.7 ± 13.7 0.054
Male 415 (60.1) 265 (58.2) 180 (65.2) 185 (52.9) 0.016
Past medical history
Hypertension 247 (35.7) 194 (42.6) 116 (42.0) 166 (47.4) 0.002
Diabetes 202 (29.2) 119 (26.2) 89 (32.2) 121 (34.6) 0.056
Coronary artery disease 105 (15.2) 53 (11.6) 33 (12.0) 35 (10.0) 0.081
Stroke 87 (12.6) 56 (12.3) 26 (9.4) 42 (12.0) 0.571
Chronic pulmonary disease 57 (8.2) 45 (9.9) 16 (5.8) 26 (7.4) 0.246
Metastatic cancer 162 (23.4) 119 (26.2) 68 (24.6) 85 (24.3) 0.777
Vital signs at shock recognition
Systolic blood pressure, mmHg 91.8 ± 24.0 92.3 ± 24.1 83.0 ± 17.5 85.7 ± 22.6 <0.001
Diastolic blood pressure, mmHg 54.7 ± 15.9 55.5 ± 16.9 51.7 ± 12.0 53.9 ± 17.6 0.016
Pulse rate, beats/min 103.6 ± 23.7 106.9 ± 23.0 105.0 ± 22.3 109.5 ± 24.1 0.001
Infection focus
Pneumonia 223 (32.3) 183 (40.2) 54 (19.6) 100 (28.6) <0.001
Urinary tract infection 142 (20.5) 103 (22.6) 85 (30.8) 116 (33.1) <0.001
Hepatobiliary and pancreas infection 133 (19.2) 74 (16.3) 76 (27.5) 73 (20.9) 0.003
Gastrointestinal infection 136 (19.7) 69 (15.2) 46 (16.7) 52 (14.9) 0.126
Laboratory findings
White blood cell count (×103/μL) 9.6 [5.1–15.3] 11.6 [5.7–17.9] 9.5 [4.5–17.0] 10.5 [4.4–17.8] 0.058
Hemoglobin, g/dL 11.1 ± 2.5 10.7 ± 2.4 11.4 ± 2.7 11.2 ± 2.6 0.001
Creatinine, mg/dL 1.1 [0.8–1.6] 1.2 [0.9–2.0] 1.7 [1.2–2.5] 2.1 [1.4–2.9] <0.001
Blood urea nitrogen, mg/dL 21.2 [15.0–31.0] 26.0 [18.7–39.0] 29.0 [20.8–40.3] 38.0 [28.0–51.9] <0.001
Aspartate transaminase, IU/L 35.0 [23.0–69.3] 35.0 [23.0–60.0] 58.0 [28.0–148.0] 45.0 [29.0–93.3] <0.001
Alanine transaminase, IU/L 23.0 [14.0–49.0] 23.0 [13.0–43.0] 35.5 [16.0–89.8] 29.0 [16.0–59.0] <0.001
Initial lactate level, mmol/L 2.9 [1.7–5.0] 2.8 [1.7–4.7] 4.0 [2.4–6.5] 4.3 [2.7–6.4] <0.001
CRP, mg/dL 5.1 [1.2–9.4] 22.0 [17.5–29.3] 5.5 [0.7–9.9] 25.0 [18.8–30.3] <0.001
PCT, ng/mL 1.2 [0.4–5.4] 3.3 [1.0–8.1] 41.8 [24.5–66.7] 46.0 [25.6–94.9] <0.001
Severity score
Maximum SOFA 7.0 [5.0–10.0] 7.0 [5.0–10.0] 9.0 [6.0–12.0] 10.0 [7.0–12.0] <0.001
APACHE-II score 18.0 [12.0–24.0] 19.0 [14.0–26.0] 19.0 [13.3–26.0] 22.0 [15.0–28.0] <0.001
28-day mortality 125 (18.1) 98 (21.5) 49 (17.8) 94 (26.9) 0.006
Table 3. Baseline and clinical characteristics of the study population using optimal cut-off values for C-reactive 
protein and procalcitonin. Values were expressed as means ± standard deviation, medians [interquartile range], 
or numbers (%). aCRP elevation ≥14.0 mg/dL. bPCT elevation ≥17.0 ng/mL Abbreviations: CRP, C-reactive 
protein; PCT, procalcitonin; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and 
Chronic Health Evaluation.
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CRP was more predictive than PCT, and elevation of both CRP and PCT was associated with the highest 
mortality rate among all combinations. However, CRP and PCT alone as well as their combination were not 
independent predictors of 28-day mortality in septic shock cases. Further studies are needed to identify the bio-
markers for early prognostication in patients with septic shock.
Methods
setting and study population. This was a multicenter prospective, observational, registry-based study 
using KoSS septic shock registry data. The KoSS, a multicenter clinical research consortium for septic shock, was 
organized in 2013, and KoSS investigators have been prospectively collecting data from septic shock patients at 
the EDs of 10 teaching hospitals throughout South Korea from October 2015. The institutional review board 
of Asan Medical Center [2015–1253] and each institution (Korea University Anam Hospital [HRPC2016-184], 
Samsung Medical Center [SMC2015-09-057], Yonsei University College of Medicine Severance Hospital [4-2015-
0929], Gangnam Severance Hospital [3-2015-0227], Seoul National University Bundang Hospital [B-1409/266-
401], Seoul National University College of Medicine [J-1408-003-599], Seoul National University Boramae 
Medical Center [16-2014-36], Hallym University College of Medicine Gangnam Secred Heart Hospital [2015-11-
142], Korea University Guro Hospital [KUGH15358-001], Hanyang University Hospital [HYUH2015-11-013-
007]) approved the study protocol, and informed consent was obtained before data collection. All experiments 
were performed in accordance with relevant guidelines and regulations17.
Adult (≥18 years) septic shock patients, defined by suspected or confirmed infection and evidence of refrac-
tory hypotension or hypoperfusion, were enrolled in the registry18–20. Refractory hypotension was defined as per-
sistent hypotension which was systolic blood pressure (SBP) <90 mm Hg, a mean arterial pressure <70 mm Hg, 
or an SBP decrease of >40 mm Hg after adequate intravenous fluid challenge (20–30 mL/kg or at least 1 L or more 
of crystalloid solution administered over 30 minutes), or as the need for vasopressors after fluid resuscitation21. 
Hypoperfusion was defined as a serum lactate concentration of ≥4 mmol/L22. Patients who signed a “Do Not 
Attempt Resuscitation” order, met the inclusion criteria six hours after ED arrival, were transferred from other 
hospitals without meeting the inclusion criteria upon ED arrival, or were directly transferred from an ED to other 
hospitals were not enrolled in in the KoSS septic shock registry. The case report form, standard definitions of 200 
variables including clinical characteristics, therapeutic interventions, and outcomes of patients with septic shock, 
and an investigator manual were developed based on a literature review and consensus by the study investigators. 
Data were collected via a standardized registry form and entered into a web-based electronic database registry. 
Outliers or incorrect values are primarily filtered by this data entry system. Additionally, the principal investigator 
of each site has a designated local research coordinator who is responsible for ensuring the accuracy of data and 
verifying records. The quality management committee (QMC), which consists of emergency physicians, local 
research coordinators, and investigators in each ED, monitors and reviews data quality regularly. The QMC gives 
feedback to each research coordinator and investigator of the results of the quality management process through 
the query function in the system or directly by phone to clarify data17.
Data collection. All KoSS septic shock registry data were collected from November 2015 to December 2017. 
Demographic and clinical data, including age, gender, previous medical history, initial vital signs, severity, and 
laboratory values on admission, and interventions were retrieved from the septic shock registry. Maximum SOFA 
and APACHE-II scores were evaluated using the worst parameters within 24 hours after ED arrival17,23.
All laboratory parameters, including CRP and PCT levels, were measured at the ED upon initial septic shock 
recognition. We determined the cut-off values of CRP and PCT to predict 28-day mortality using the Youden 
Index and divided patients into subgroups as follows: both CRP and PCT not elevated, only CRP or PCT elevated, 
and both CRP and PCT elevated.
The primary clinical outcome of this study was the 28-day mortality rate. We evaluated the predictive ability 
of CRP, PCT, and their combination for 28-day mortality rates.
statistical analyses. Continuous variables were expressed as means ± standard deviation or medians with 
the interquartile range if the assumption of a normal distribution was violated. Categorical variables were expressed 
as numbers and percentages. To analyze the baseline characteristics and laboratory examinations in survivor and 
non-survivor groups, Student’s t-test was used to compare the means of normally distributed continuous variables; 
the Mann-Whitney U test was used to compare non-continuous variables. The Chi-squared or Fisher’s exact test was 
used to compare categorical variables17. The optimal cut-off value of CRP was predicted by the Youden Index using 
ROC curve analysis in a univariate model. Multivariate analyses were performed using a logistic regression with a 
backward elimination method to evaluate the association between the clinical factors, including laboratory data and 
28-day mortality. The results of the multivariate logistic regression were reported as OR and 95% CI. We conducted 
an Analysis of Variance and Kruskal-Wallis analysis to evaluate differences between subgroup analyses.
All tests in this study were two-sided, and a p-value < 0.01 was considered to be statistically significant. All 
statistical analyses were performed using SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL, USA).
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